Android Apple
  • Home
  • Stock Market News
  • Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease

Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease

By Yahoo! Finance   |   3 months ago
Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease

Miplyffa, in combination with Johnson & Johnson's enzyme inhibitor Zavesca, is approved by the FDA to treat neurological symptoms in adults and children with NPC, a rare genetic disease. This marks a significant advancement in treating this condition.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.